Neonatal Opiate Withdrawal Syndrome in COVID-19: Are hospitalized infants with NOWS experiencing more severe clinical illness
associated with COVID-19 related changes in hospital infection control policies and practices?
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BACKGROUND

METHODS

METHODS

Pregnant women with opiate use disorder have high-risk pregnancies and require
specialized medical care throughout their pregnancy. Newborns that are exposed to
opiates during pregnancy are at risk for experiencing neonatal opiate withdrawal
syndrome (NOWS). Infants with NOWS may experience symptoms including poor
feeding, poor sleep, excessive crying, and difficulty with consoling. Severe forms of
NOWS may result in excessive vomiting and diarrhea with subsequent dehydration,
seizures, and even death. Infants born to mothers with opiate use disorder must be
hospitalized after their birth for evaluation and appropriate management of NOWS.
Physicians commonly evaluate babies with NOWS using the Finnegan Scale tool (see
Table 1) or the Eat, Sleep, Console tool.

Data will be extracted from the electronic medical record (EMR) by UNM Clinical and Translational
Science Center (UNM CTSC), de-identified and pooled by an Honest Broker. Demographic information
including infant sex, ethnicity, race, and county of mother’s residence will be obtained. Additionally,
information from the pregnancy (see Table 2) will be collected including gestational age at time of
delivery, growth parameters of the infant, what the prenatal substance exposure included, and any
additional pregnancy complications (such as maternal diabetes or pre-eclampsia).

Table 2: Summary of Maternal and Infant Characteristics to
be Obtained

The SARS-CoV-2 pandemic has forced hospitals to implement increasingly
escalating infection control practices to prevent nosocomial disease. At the University
of New Mexico Hospital, multiple practices were adapted on April 15, 2020. These
included:
• Mandated universal masking of all staff, providers, visitors
• Limitations in visitation, with volunteers and cuddlers no longer permitted in the
hospital
• Infants limited to one parent at the bedside at a time in the Intermediate Care
Nursery and the Newborn Intensive Care Unit
These interventions directly impact the ability of families, providers, and staff to
provide optimal non-pharmacological interventions for this vulnerable population.
This raises the concern that more infants with NOWS may require pharmacological
intervention to manage their symptoms. Additionally, having masked caregivers may
result in additional agitation for the infants. Together, the impact of these infection
control practices for infants with NOWS may result in additional stressors during a
period of intense tension for the infants.

Control

To identify infants that qualify, the following ICD-10 codes for newborns suspected to be affected by
maternal use of other drugs of addiction are being used:
• P96.1
• P04.49
• P04.9
• P04.41
All infants included in the study will be divided into two cohorts: pre-COVID and COVID, to represent
the population born prior to the pandemic and those born during the pandemic. Infant must be discharge
between the following dates to be included:
• Pre-COVID: June 1, 2019 – February 29, 2020
• COVID: April 15, 2020 - December 31, 2020
Information on maternal COVID status, including infection and vaccination, will be collected when
available.
All infants must be discharged from the intermediate care nursery at UNM Hospital, as we aim to assess
pharmacological intervention differences in the two cohorts.
The outcomes to be analyzed for both cohorts include:
• Finnegan Scale assessments
• Pharmacological intervention required
• Dosing of pharmacological intervention (including the highest dose and the total amount received)
• Utilization of secondary pharmacological intervention
• Length of hospital stay
Upon completion of the data extraction, statistical analysis will be completed.
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Table 1: Summary of the Finnegan Scale

STUDY OBJECTIVE
Given the recent changes required to improve infection control during the pandemic,
we hypothesized that infants with NOWS born during this period will have a more
complicated hospital course.
Specifically, we aim to evaluate NOWS severity, defined as utilization of
pharmacological intervention and length of treatment, combined with length of
hospital stay in infants born prior to the pandemic with the diagnosis of NOWS
(discharged between June 1, 2019 – February 29, 2020). These findings will be
compared with a sample of infants born during the pandemic with a diagnosis of
NOWS (discharged between April 15, 2020 – December 31, 2020).

Body System

Symptoms

Scores (Ranges)

Central Nervous

High Pitched Cry, Poor
Sleep, Moro Reflex
(startle), Tremors, Muscle
Tone, Convulsions

1-5

Metabolic /
Somatic /
Respiratory

Sweating, Fever, Yawning,
Stuffiness, Elevated
Respiratory Rate

1-3

Gastrointestinal

Excessive Sucking, Poor
Feeding, Vomiting, Loose
Stools

1-3

Table 1 shows a summary of the Finnegan Scale. There are three main body systems evaluated, and infants
are evaluated every 3-4 hours. Elevation in the scores will prompt providers to discuss additional intervention
to manage symptoms, include pharmacological intervention. If an infant receives three consecutive scores of
≥8 or one score >12, pharmacological intervention may be initiated. The medications commonly used include
morphine or methadone, with clonidine often used as a secondary medication. Infants remain hospitalized
throughout the duration of pharmacological therapy, which can last weeks to months.

Demographic
Information

Pregnancy Information

COVID
Information

Infant Sex

Gestational Age at Delivery

Maternal
Infection with
COVID

Infant Ethnicity

Growth Parameters for
Infant

Maternal COVID
vaccination

Infant Race

Prenatal Substance
Exposure(s)

Mother’s County of
Residence

Pregnancy Complications
(including diabetes, preeclampsia)

Table 2 shows a summary of the maternal and infant characteristics that will be
collected. This includes demographic information, pregnancy information, and any
information about COVID infection and/or vaccination in the mother.

STUDY PROGRESS
Approval by the Institutional Review Board (IRB) has been obtained and the
request for utilization of the Honest Broker has been submitted. Currently, the
data extraction is ongoing.
Once the de-identified data set has been created, data analysis will commence.
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